Soluble guanylate cyclase modulators in heart failure

Current Heart Failure Reports

Volumn 8, Issue 1, 2011, Pages 38-44

  Mitrovic, Veselin ^a   Jovanovic, Ana ^a   Lehinant, Stefan ^a  

^a KERCKHOFF HEART CENTER   (Germany)

Author keywords

Cyclic guanosine monophosphate; Guanylate cyclase; Heart failure; sCG stimulator Cinaciguat; sGC activator Riociguat

Indexed keywords

3 [2 (4 CHLOROPHENYLTHIO)PHENYL] N (4 DIMETHYLAMINOBUTYL)ACRYLAMIDE; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ATRIAL NATRIURETIC FACTOR; BAY 604552; BRAIN NATRIURETIC PEPTIDE; CINACIGUAT; CYCLIC GMP; GUANYLATE CYCLASE; GUANYLATE CYCLASE ACTIVATOR; HEME; LIFICIGUAT; NATRIURETIC PEPTIDE TYPE C; NESIRITIDE; NITRIC OXIDE; ORGANIC NITRATE; REACTIVE OXYGEN METABOLITE; RIOCIGUAT; UNCLASSIFIED DRUG; URODILATIN;

ACUTE DECOMPENSATED HEART FAILURE; ADD ON THERAPY; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CONGESTIVE HEART FAILURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ECHOCARDIOGRAPHY; FUNCTIONAL STATUS; GLOMERULUS FILTRATION RATE; HEART AFTERLOAD; HEART FAILURE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART PRELOAD; HUMAN; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; OXIDATIVE STRESS; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SIDE EFFECT; SIGNAL TRANSDUCTION; SYSTEMIC VASCULAR RESISTANCE; VASODILATATION;

BENZOIC ACIDS; CARDIOVASCULAR AGENTS; GUANYLATE CYCLASE; HEART FAILURE; HUMANS; HYPERTENSION, PULMONARY; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 79551534866     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0045-1     Document Type: Article

References (36)

1. Stuart S, MacIntyre K, Hole DJ, et al.: More 'malignant' than cancer? Five-year survival following a first admission for heart failure. Eur J Heart Fail 2001; 3(3): 315-322)
2. F Grigioni L Potena N Galiè, et al. 2006 Prognostic implications of serial assessments of pulmonary hypertension in severe chronic heart failure J Heart Lung Transplant. 25 1241 1246 17045937 10.1016/j.healun.2006.06.015 (Pubitemid 44528289)
3. Evgenov OV, Pacher P, Schmidt PM, et al.: NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat.Rev.Drug Discov.2006.Sep.;5(9.):755.-68. 2006, 5:755-768
4. RT Schermuly JP Stasch SS Pullamsetti, et al. 2008 Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension Eur Respir J. 32 881 891 1:CAS:528:DC%2BD1cXht1KqsbjM 18550612 10.1183/09031936. 00114407
5. •• Stasch JP, Hobbs AJ: NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol. 2009; (191): 277-308. This is an excellent overview of background of effects of NO-independent sGC stimulators.
6. Ghofrani HA, Hoeper MM, Hoeffken G, et al.: Riociguat Dose Titration in Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) or Pulmonary Arterial Hypertension (PAH). Conference abstract. 2009 American Thoracic Society International Conference, San Diego, USA, 16-20 May 2009.
7. Mitrovic V, Swidnicki B, Ghofrani A, et al.: Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure. Conference abstract. 4th International Conference on cGMP, Regensburg, Germany, 19-21 Jun 2009.
8. Feil R, Kemp-Harper B: cGMP signalling: from bench to bedside. Conference on cGMP generators, effectors and therapeutic implications. EMBO Rep.2006.Feb.;7.(2):149.-53. 2006, 7:149-153
9. Lucas KA, Pitari GM, Kazerounian S, et al.: Guanylyl cyclases and signaling by cyclic GMP. Pharmacol.Rev.2000.Sep.;52.(3):375.-414. 2000, 52:375-414
10. 1•• Mitrovic V, Hernandez AF, Meyer M, et al.: Role of guanylate cyclase modulators in decompensated heart failure. Heart Fail.Rev.2009.Dec.;14(4):309.-19. 2009, 14:309-319. This is a first-time overview of effects of pGC and sGC modulators in patients with heart failure. Natriuretic peptides (nesiritide and ularitide) lead to an increase of cGMP through stimulation of pGC; however. sGC stimulators and activators lead to an increase of intracellular cGMP through modulation of soluble guanylate cyclase.
11. Joseph L, Jr. Izzo, American Council on High Blood Pressure, and Henry R.Black: Hypertension Primer: The Essentials of High Blood Pressure 2003:Chapter A3, 8-13
12. Burnett JC Jr.: Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon. J.Cardiol.2006.Nov.;48.(5): 235.-41. 2006, 48:235-241
13. Lee CY, Burnett, JC Jr.: Natriuretic peptides and therapeutic applications. Heart Fail.Rev.2007.Jun.;12.(2):131.-42. 2007, 12:131-142
14. Clerico A, Iervasi G, Pilo A.: Turnover studies on cardiac natriuretic peptides: methodological, pathophysiological and therapeutical considerations. Curr.Drug Metab.2000.Jul.;1(1):85.-105. 2000, 1:85-105
15. M Volpe C Tritto N De Luca, et al. 1991 Failure of atrial natriuretic factor to increase with saline load in patients with dilated cardiomyopathy and mild heart failure J. Clin. Invest. 88 1481 1489 1:STN:280: DyaK38%2Fkt1OgsA%3D%3D 1834698 10.1172/JCI115458
16. • Pacher P, Beckman JS, Liaudet L: Nitric oxide and peroxynitrite in health and disease. Physiol Rev.2007.Jan.;87.(1):315.-424. 2007, 87:315-424. This paper describes the role of oxidative stress in cardiovascular disease.
17. SA Atlas T Maack 1987 Effects of atrial natriuretic factor on the kidney and the renin-angiotensin-aldosterone system Endocrinol. Metab Clin. North Am. 16 107 143 1:CAS:528:DyaL2sXltV2nu74%3D 2962862 (Pubitemid 18088765)
18. van der Zander K, Houben AJ, Hofstra L, et al.: Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, placebo-controlled crossover study. Am.J.Physiol Heart Circ.Physiol.2003.Sep. ;285.(3):H1206.-12.Epub.2003.May.8. 2003, 285:H1206-H1212
19. Mills RM, LeJemtel TH, Horton DP, et al.: Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J.Am.Coll.Cardiol. 1999, 34:155-162
20. Sackner-Bernstein JD, Skopicki HA, Aaronson KD: Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. Circulation.2005.Mar.29.;111.(12.):1487.-91.Epub.2005.Mar.21. 2005, 111:1487-1491
21. Luss H, Mitrovic V, Seferovic PM, Simeunovic D, et al. Renal effects of ularitide in patients with decompensated heart failure. Am.Heart J.2008.Jun.;155.(6.):1012.e1.-8. 2008, 155:1012-1018
22. Mitrovic V, Seferovic PM, Simeunovic D, et al.: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur.Heart J.2006.Dec.;27.(23):2823.-32.Epub.2006.Oct.30. 2006, 27:2823-2832
23. Su J, Scholz PM, Weiss HR: Differential effects of cGMP produced by soluble and particulate guanylyl cyclase on mouse ventricular myocytes. Exp.Biol.Med.(Maywood.).2005.Apr;230.(4):242.-50. 2005, 230:242-250
24. RG Knowles S Moncada 1994 Nitric oxide synthases in mammals Biochem. J. 298 Pt 2 249 258 1:CAS:528:DyaK2cXitlyksbg%3D 7510950
25. KE Torfgard J Ahlner 1994 Mechanisms of action of nitrates Cardiovasc. Drugs Ther. 8 701 717 1:STN:280:DyaK2M7nvVCjtA%3D%3D 7873467 10.1007/BF00877117 (Pubitemid 24376750)
26. Packer M, Lee WH, Kessler PD, et al.: Prevention and reversal of nitrate tolerance in patients with congestive heart failure. N.Engl.J.Med. 1987, 317:799-804 (Pubitemid 17136471)
27. J Foerster C Harteneck J Malkewitz, et al. 1996 A functional heme-binding site of soluble guanylyl cyclase requires intact N-termini of alpha 1 and beta 1 subunits Eur. J. Biochem. 240 380 386 1:CAS:528:DyaK28XlsF2gt7w%3D 8841402 10.1111/j.1432-1033.1996.0380h.x
28. LJ Ignarro JB Adams PM Horwitz, et al. 1986 Activation of soluble guanylate cyclase by NO-hemoproteins involves NO-heme exchange. Comparison of heme-containing and heme-deficient enzyme forms J. Biol. Chem. 261 4997 5002 1:CAS:528:DyaL28Xit1Whtrs%3D 2870064
29. • Boerrigter G, Costello-Boerrigter LC, Cataliotti A, et al.: Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure. Hypertension 2007. 49:1128-1133. The authors show that sGC activators act by an oxidized form of sGC, in contrast to sGC stimulators, which exert their effect through a reduced variant of sGC.
30. G Boerrigter LC Costello-Boerrigter A Cataliotti, et al. 2007 Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure BMC Pharmacology 7 P9 10.1186/1471-2210-7-S1-P9
31. R Frey W Muck S Unger, et al. 2008 Pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase activator cinaciguat (BAY 58-2667) in healthy male volunteers J Clin Pharmacol 48 1400 1410 1:CAS:528:DC%2BD1cXhsFCrs7jK 18779378 10.1177/0091270008322906
32. H Lapp V Mitrovic N Franz, et al. 2007 BAY 58-2667, a soluble guanylate cyclase activator, improves cardiopulmonary haemodynamics in acute decompensated heart failure and has a favourable safety profile BMC Pharmacology. 7 S9 10.1186/1471-2210-7-S1-S9
33. Mitrovic V, Lapp H, Franz N, et al.: The soluble guanylate cyclase activator cinaciguat (BAY 58-2667) has a favourable safety profile and improves cardiopulmonary haemodynamics in acute decompensated heart failure. Poster presented at Heart Failure 2008, 14-17 June, Milan, Italy.
34. •• Lapp H, Mitrovic V, Franz N, et al.: Cinaciguat (BAY 58 2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart failure. Circulation. Published online May 18, 2009. This is a first-time description of the hemodynamic effects of the sGC activator cinaciguat in patients with decompensated heart failure as a new promising model for therapy.
35. Erdmann E, Semigran MJ, Nieminen MS, et al.: Cinaciguat, a soluble Guanylate Cyclase Activator, unloads the heart in acute decompensated heart failure. Cinaciguat phase IIb abstract for ACC 2010.
36. Kemp-Harper B, Feil R. Meeting report: cGMP matters. Sci Signal. 2008 Mar 4;1(9):pe12.